Temperature-sensitive liposomal formulation

• US 7,901,709 B2
• Filed: 04/12/2005
• Issued: 03/08/2011
• Est. Priority Date: 06/18/1998
• Status: Expired due to Fees

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Needham, David
• Primary Examiner(s): Kishore; Gollamudi S
• Application Number:
  US11/103,587
• Publication Number:
  US 20050191345A1
• Time in Patent Office: 2,156 Days
• Field of Search: 424/450, 264/4.1, 264/4.3, 264/4.6
• US Class Current: 424/450
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase.

Claims

1. A method for loading active agents into liposomes, comprising:

(a) providing a liposome comprising a gel-phase lipid bilayer, said lipid bilayer comprising dipalmitoylphosphatidylcholine (DPPC) and monostearoylphosphatidylcholine (MSPC), wherein the DPPC and the MSPC are present in the lipid bilayer in a molar ratio ranging from about 95;

5 to about 80;

20, and wherein said lipid bilayer is present below its phase transition temperature; and

(b) exposing the lipid bilayer to an active agent at a temperature below the phase transition temperature of the lipid bilayer to load the liposome interior with the active agent, wherein the active agent is loaded into the liposome at the temperature below the phase transition temperature of the lipid bilayer.

2. The method according to claim 1, wherein the active agent is a pharmacologically active agent, a flavor agent, diagnostic agent or nutritional agent.

3. The method according to claim 1, wherein the active agent is platelet activating factor.

4. The method of claim 1, wherein the DPPC is present in the lipid bilayer at about 90% mol %, and the MSPC is present in the lipid bilayer at about 10 mol %.

5. The method of claim 1, wherein the active agent is an antineoplastic agent.

6. The method of claim 1, wherein the active agent is doxorubicin.

7. The method of claim 1, wherein the active agent is a camptothecin.

8. The method of claim 6, wherein at least 80% of the doxorubicin to which the lipid bilayer is exposed is loaded into the liposome.

16. The method of claim 1, wherein the active agent is an anthracycline antibiotic.

18. The method of claim 1, wherein said gel-phase lipid bilayer further comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethyleneglycol) 2000] (DSPE-PEG-2000).

9. A method for loading an antineoplastic agent into liposomes, comprising:

(a) providing a liposome comprising a gel-phase lipid bilayer, said lipid bilayer comprising dipalmitoylphosphatidylcholine (DPPC) and monostearoylphosphatidylcholine (MSPC), wherein the DPPC and the MSPC are present in the lipid bilayer in a molar ratio ranging from about 95;

5 to about 80;

20, and wherein said lipid bilayer is present below its phase transition temperature; and

(b) exposing the lipid bilayer to an antineoplastic agent at a temperature below the phase transition temperature of the lipid bilayer to load the liposome interior with the antineoplastic agent, wherein the antineoplastic agent to which the lipid bilayer is exposed is loaded into the liposome at the temperature below the phase transition temperature of the lipid bilayer.

10. The method of claim 9, wherein the DPPC is present in the lipid bilayer at about 90 mol %, and the MSPC is present in the lipid bilayer at about 10 mol %.

11. The method of claim 9, wherein the antineoplastic agent is doxorubicin.

12. The method of claim 9, wherein the antineoplastic agent is a camptothecin.

13. The method of claim 9, wherein the antineoplastic agent is cisplatin.

14. The method of claim 9, wherein the antineoplastic agent is paclitaxel.

15. The method of claim 9, wherein the antineoplastic agent is docetaxol.

17. The method of claim 9, wherein the active agent is selected from the group consisting of:

daunorubicin, carinomycin, rubidazone, epirubicin, vincristine, and vinblastine.